Autopsy report · NCT00353574
DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension
Cause of deathFutility
“Study DAR-312 did not meet primary co-endpoints”
Life of this trial
- Registered 2 months before it started.
- Ran for about 3 years 7 months before it stopped.
- 282 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Gilead Sciences
- Sponsor type
- Industry
- Conditions
- Hypertension
- Interventions
- Darusentan
- Participants
- 282
- Sites
- 75
- Countries
- Argentina, Brazil, Canada, Denmark, France, Sweden, United Kingdom, United States
Trials that died the same way
- A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
“At the time of the primary analysis, results did not meet the primary endpoint”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.